Gouping Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gouping Ding has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Xiaodong Wang
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
5 shared publications - Junjie Wang
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
4 shared publications - Qianqian Wang
Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University
4 shared publications - Yeqian Feng
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
4 shared publications - Yiping Huang
Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China
3 shared publications - Jing He
Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China
2 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Springer Nature in Cancer Cell International
Artificial intelligence for predicting immune checkpoint inhibitor outcomes through multi-omics integration
- 26 October 2026
- Published by Springer Nature in Cancer Cell International
Open AccessArtificial intelligence for predicting immune checkpoint inhibitor outcomes through multi-omics integration
- Open Access
- 26 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Molecular and AI enabled prognostication in endometrial cancer a 2015 to 2024 bibliometric Atlas and critical review
Background Endometrial cancer (EC) is a leading gynecologic malignancy with increasing incidence and mortality, particularly in high-income countries. Traditional prognostic models based on clinicopathological features often fail to accurately stratify risk, especially in early-stage and low-risk cases. Methods A bibliometric analysis was performed on research articles published between 2015 and 2024, sourced from the Web of Science and Scopus databases. The analysis included publications on prognostic or risk models in EC and assessed key trends and themes within the field. Results The study reveals a significant shift toward molecular-based stratification, particularly with the Cancer Genome Atlas (TCGA) subtypes, and the incorporation of AI-driven models. Molecular markers, such as POLE-ultramutated and p53-abnormal tumors, alongside biomarkers like HE4 and L1CAM, offer improved prognostic accuracy. AI models, including radiomics and deep learning approaches, show promise in predicting disease recurrence and patient outcomes. Conclusion Advances in molecular classification and AI have improved EC prognostication. However, challenges remain in prospective validation and broader clinical implementation. Future research should focus on multi-omics integration and international collaboration to improve the accuracy and applicability of EC prognostic models. Graphical Abstract
- 26 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessMolecular and AI enabled prognostication in endometrial cancer a 2015 to 2024 bibliometric Atlas and critical review
Background Endometrial cancer (EC) is a leading gynecologic malignancy with increasing incidence and mortality, particularly in high-income countries. Traditional prognostic models based on clinicopathological features often fail to accurately stratify risk, especially in early-stage and low-risk cases. Methods A bibliometric analysis was performed on research articles published between 2015 and 2024, sourced from the Web of Science and Scopus databases. The analysis included publications on prognostic or risk models in EC and assessed key trends and themes within the field. Results The study reveals a significant shift toward molecular-based stratification, particularly with the Cancer Genome Atlas (TCGA) subtypes, and the incorporation of AI-driven models. Molecular markers, such as POLE-ultramutated and p53-abnormal tumors, alongside biomarkers like HE4 and L1CAM, offer improved prognostic accuracy. AI models, including radiomics and deep learning approaches, show promise in predicting disease recurrence and patient outcomes. Conclusion Advances in molecular classification and AI have improved EC prognostication. However, challenges remain in prospective validation and broader clinical implementation. Future research should focus on multi-omics integration and international collaboration to improve the accuracy and applicability of EC prognostic models. Graphical Abstract
- Open Access
- 7 February 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Rewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation
Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 can produce durable remissions in multiple solid tumors, yet primary and acquired resis
- 7 February 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Open AccessRewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation
Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 can produce durable remissions in multiple solid tumors, yet primary and acquired resis
- Top Cited PapersOpen Access
- 23 January 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (2) , 189536
Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade
- 23 January 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (2) , 189536
Top Cited PapersOpen AccessPrecision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade
- Open Access
- 17 December 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1)
Mapping the landscape of predictive biomarkers for immune checkpoint inhibitors a bibliometric analysis
This large-scale bibliometric analysis maps the global research landscape of predictive biomarkers for immune checkpoint inhibitors (ICIs) from 2011 to 2025. Leveraging 9,075 publications from the Web of Science Core Collection, we used co-citation, co-authorship, and keyword co-occurrence analyses to quantify publication dynamics, collaborative networks, and conceptual evolution. China produced the most publications (1,923, a country-level count reflecting multi-national co-authorship), while the United States led in influence as reflected by high-impact institutions (e.g., MD Anderson Cancer Center) and prolific authors (e.g., Kurzrock R, H-index 116). The strongest international collaboration was between the USA and China (276 co-authored publications). Thematic evolution revealed a paradigm shift from reliance on single biomarkers (e.g., PD-L1, tumor mutational burden [TMB]) toward integrated multi-omics signatures that incorporate tumor microenvironment features and advanced computational approaches. Keyword analysis highlighted artificial intelligence (n = 640), radiomics, and liquid biopsy as emerging frontiers. Notably, gastroesophageal junction cancers exhibited the strongest citation burst (strength = 11.53), highlighting unresolved tumor-specific controversies such as the predictive validity of PD-L1 in this setting. However, significant translational barriers remain: lack of biomarker assay standardization, high analytical variability (e.g., differing PD-L1 immunohistochemistry clones and inconsistent TMB cutoff thresholds), and insufficient clinical validation. This study provides an evidence-based overview to guide future research toward multi-omics integration, prospective validation, and cross-disciplinary collaboration, thereby advancing precision immuno-oncology.
- 17 December 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1)
Open AccessMapping the landscape of predictive biomarkers for immune checkpoint inhibitors a bibliometric analysis
This large-scale bibliometric analysis maps the global research landscape of predictive biomarkers for immune checkpoint inhibitors (ICIs) from 2011 to 2025. Leveraging 9,075 publications from the Web of Science Core Collection, we used co-citation, co-authorship, and keyword co-occurrence analyses to quantify publication dynamics, collaborative networks, and conceptual evolution. China produced the most publications (1,923, a country-level count reflecting multi-national co-authorship), while the United States led in influence as reflected by high-impact institutions (e.g., MD Anderson Cancer Center) and prolific authors (e.g., Kurzrock R, H-index 116). The strongest international collaboration was between the USA and China (276 co-authored publications). Thematic evolution revealed a paradigm shift from reliance on single biomarkers (e.g., PD-L1, tumor mutational burden [TMB]) toward integrated multi-omics signatures that incorporate tumor microenvironment features and advanced computational approaches. Keyword analysis highlighted artificial intelligence (n = 640), radiomics, and liquid biopsy as emerging frontiers. Notably, gastroesophageal junction cancers exhibited the strongest citation burst (strength = 11.53), highlighting unresolved tumor-specific controversies such as the predictive validity of PD-L1 in this setting. However, significant translational barriers remain: lack of biomarker assay standardization, high analytical variability (e.g., differing PD-L1 immunohistochemistry clones and inconsistent TMB cutoff thresholds), and insufficient clinical validation. This study provides an evidence-based overview to guide future research toward multi-omics integration, prospective validation, and cross-disciplinary collaboration, thereby advancing precision immuno-oncology.
- Open Access
- 25 August 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-13
Global research trends in PARP inhibitors for ovarian cancer: a bibliometric analysis
This bibliometric analysis maps global research trends on PARP inhibitors (PARPis) in ovarian cancer from January 2021 to May 2025, utilizing 1,434 publications retrieved from the Web of Science Core Collection. Employing Bibliometrix, VOSviewer, and CiteSpace, the study quantifies contributions across countries, institutions, authors, and research foci. Key findings reveal the United States (440 publications) and China (352) as leading producers, with UNICANCER (287 publications) and Memorial Sloan Kettering Cancer Center (61) as top institutions. Keyword clustering identified six research themes: PARPi resistance mechanisms (Cluster 1, red) emerged as the dominant focus, followed by immunotherapy combinations for platinum-resistant disease (Cluster 2, green), maintenance therapy (Cluster 3, blue), BRCA mutations (Cluster 4, yellow), applications beyond ovarian cancer (Cluster 5, purple), and anti-angiogenic mechanisms (Cluster 6, light blue). Temporal analysis highlighted an evolution from foundational research (e.g., DNA repair pathways) toward clinical translation (e.g., maintenance therapy optimization). Notable citation bursts surrounded clinical milestones, including the SOLO1 trial’s 7-year overall survival data (burst strength: 23.99), underscoring the field’s emphasis on survival outcomes. Critical gaps persist in understanding resistance mechanisms and developing immuno-combination strategies, which constituted only 4.8% of keyword frequency. The study underscores the need for intensified research into resistance mitigation and transnational collaboration, particularly between established Euro-American networks and emerging East Asian hubs, to address therapeutic challenges and optimize clinical impact.
- 25 August 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-13
Open AccessGlobal research trends in PARP inhibitors for ovarian cancer: a bibliometric analysis
This bibliometric analysis maps global research trends on PARP inhibitors (PARPis) in ovarian cancer from January 2021 to May 2025, utilizing 1,434 publications retrieved from the Web of Science Core Collection. Employing Bibliometrix, VOSviewer, and CiteSpace, the study quantifies contributions across countries, institutions, authors, and research foci. Key findings reveal the United States (440 publications) and China (352) as leading producers, with UNICANCER (287 publications) and Memorial Sloan Kettering Cancer Center (61) as top institutions. Keyword clustering identified six research themes: PARPi resistance mechanisms (Cluster 1, red) emerged as the dominant focus, followed by immunotherapy combinations for platinum-resistant disease (Cluster 2, green), maintenance therapy (Cluster 3, blue), BRCA mutations (Cluster 4, yellow), applications beyond ovarian cancer (Cluster 5, purple), and anti-angiogenic mechanisms (Cluster 6, light blue). Temporal analysis highlighted an evolution from foundational research (e.g., DNA repair pathways) toward clinical translation (e.g., maintenance therapy optimization). Notable citation bursts surrounded clinical milestones, including the SOLO1 trial’s 7-year overall survival data (burst strength: 23.99), underscoring the field’s emphasis on survival outcomes. Critical gaps persist in understanding resistance mechanisms and developing immuno-combination strategies, which constituted only 4.8% of keyword frequency. The study underscores the need for intensified research into resistance mitigation and transnational collaboration, particularly between established Euro-American networks and emerging East Asian hubs, to address therapeutic challenges and optimize clinical impact.